Effect of corticosteroid injection in treatment of carpal tunnel syndrome

Evaluation the effect of corticosteroid injection with and without sonography guide in electro-diagnostic and clinical findings of patients with carpal tunnel syndrome

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017010831833N1

Enrollment

Registered

2017-02-19

Start date

2016-09-29

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carpal Tunnel Syndrome. Carpal Tunnel Syndrome

Interventions

Intervention 1: depomedrol injection ultrasound guided. Intervention 2: blind depomedrol injection.

Treatment - Other

depomedrol injection ultrasound guided

blind depomedrol injection

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: inclusion criteria: patients with CTS symptomes; positive tinnel, phalen and compression tests; who had moderate to severe CTS according to electrodiagnostic criteria; refuse surgery; are older than 18 and accept to inject corticosteroid exclusion criteria: pregnancy; presence of metabolic disorders that cause secondary CTS such as diabetes mellitus, thyroid disease; chronic kidney disease; rheumatological disorders; wrist fractures; having had corticosteroid injection before the study; conditions mimicking CTS such as cervical radiculopathy, polyneuropathy, brachial plexopathy, thoracic outlet syndrome; having had physical or medical therapy in the previous month; having had previous wrist surgery; having thenar muscle atrophy; patient refusal to continue the follow-ups.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Symptom Severity Scale. Timepoint: befor, 1and 3 months after. Method of measurement: questionary.;Functional Status Scale. Timepoint: befor, 1and 3 months after. Method of measurement: questionary.;Median nerve sensory latency. Timepoint: befor, 1and 3 months after. Method of measurement: EDX study.;Median nerve motor latency. Timepoint: befor, 1and 3 months after. Method of measurement: EDX study.	—

Measure

Time frame

Symptom Severity Scale. Timepoint: befor, 1and 3 months after. Method of measurement: questionary.;Functional Status Scale. Timepoint: befor, 1and 3 months after. Method of measurement: questionary.;Median nerve sensory latency. Timepoint: befor, 1and 3 months after. Method of measurement: EDX study.;Median nerve motor latency. Timepoint: befor, 1and 3 months after. Method of measurement: EDX study.

—

Secondary

Measure	Time frame
Grade. Timepoint: before, 1 and 3 months after. Method of measurement: EDX study.;Sensory NCV. Timepoint: before, 1 and 3 months after. Method of measurement: EDX study.;SNAP amp. Timepoint: before, 1 and 3 months after. Method of measurement: EDX study.;CMAP amp. Timepoint: before, 1 and 3 months after. Method of measurement: EDX study.;Side effects. Timepoint: imediate, 1 and 3 months after. Method of measurement: questionary.	—

Measure

Time frame

Grade. Timepoint: before, 1 and 3 months after. Method of measurement: EDX study.;Sensory NCV. Timepoint: before, 1 and 3 months after. Method of measurement: EDX study.;SNAP amp. Timepoint: before, 1 and 3 months after. Method of measurement: EDX study.;CMAP amp. Timepoint: before, 1 and 3 months after. Method of measurement: EDX study.;Side effects. Timepoint: imediate, 1 and 3 months after. Method of measurement: questionary.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Zahra Azimi

Physical Medicine and Rehabilitation department

z_azimi@edc.mui.ac.ir+98 31 3688 5555

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026